Knowledge graph · Drug
Hydroxycarbamide
small molecule
- Identifier
- CI-DRUG-00000787
- Entity page
- /drug/hydroxycarbamide ↗
- Edges
- 39
- Neighbours
- 16 cancers3 genes2 trials2 approvals
- Drawn
- 23 of 23 neighbours (cap 60); table lists every fetched edge
Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.
Most connectedLung Non-Small Cell Carcinoma 3,149Malignant Colorectal Neoplasm 1,866ABL1 298EGFR 276Imatinib 450Dasatinib 321
Neighbourhood
Radial view
Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.
Edges
Every edge, grouped by relationship
Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.
| Relationship | Neighbour | Direction | Evidence level | Cancer context | Support | Claim | Source | Expand |
|---|---|---|---|---|---|---|---|---|
| Hydroxycarbamide approved for …APPROVED_FORderived2 of 2 | ||||||||
| → approved for | EMA · EU · 2019Xromi is indicated for the prevention of vaso-occlusive complications of Sickle Cell Disease in patients over 9 months of age. EMA (EU) · approved · 2019-07-01 · Xromi is indicated for the prevention of vaso-occlusive complications of Sickle Cell Disease in patients over 9 months of age. | — | approved | not mapped | 1 | Regulatory | ema | open ↗ |
| → approved for | EMA · EU · 2007Siklos is indicated for the prevention of recurrent painful vaso-occlusive crises including acute chest syndrome in paediatric and adult patients suffering from symptomatic sickle-cell syndrome. | |||||||